



Multicentric Randomized Phase II/III Study

ROCSAN (Recurrent Ovarian-Uterus CarcinoSarcoma Anti-PD 1 Niraparib)



Stratification:

- PS: 0/1 vs 2
- Number of previous lines: 1 or > +
- Initial FIGO stage: I/II vs III/IV
- (Ov vs Ut)

- Endometrial carcinosarcoma & Ovarian Carcinosarcoma
- Endpoints RR/PFS for 1st step, then 1st EP OS, 2nd EP PFS, safety & translational
- Alpha 5%, power 80%, 150 events recruitment 36 months

- Protocol accepted by TESARO
- Contract on going
- Authorities Q4 2018
- 1stpatient Q1 2019
- Please contact GINECO
- Translational program via EU grant (TranscanBio)